Clinicopathological characteristics and prognostic factors in combined hepatocellular carcinoma and cholangiocarcinoma.
10.14701/kjhbps.2013.17.4.152
- Author:
Sang Eun PARK
1
;
Sung Ha LEE
;
Jae Do YANG
;
Hong Pil HWANG
;
Si Eun HWANG
;
Hee Chul YU
;
Woo Sung MOON
;
Baik Hwan CHO
Author Information
1. Department of Surgery, Chonbuk National University Medical School and Hospital, Jeonju, Korea. hcyu@jbnu.ac.kr
- Publication Type:Original Article
- Keywords:
Combined hepatocellular cholangiocarcinoma;
Survival rate;
Prognostic factors
- MeSH:
Carcinoma, Hepatocellular*;
Cholangiocarcinoma*;
Disease-Free Survival;
Humans;
Joints;
Liver Neoplasms;
Multivariate Analysis;
Prognosis;
Retrospective Studies;
Survival Rate
- From:Korean Journal of Hepato-Biliary-Pancreatic Surgery
2013;17(4):152-156
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUNDS/AIMS: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer that has rarely been reported in detail. This study was performed in order to evaluate the clinicopathological characteristics and prognostic factors of cHCC-CC in single center. METHODS: The clinicopathological features of patients diagnosed and operated with cHCC-CC at Chonbuk National Hospital between July 1998 and July 2007 were retrospectively studied by comparing them with patients with only hepatocellular carcinoma (HCC) who had undergone a hepatic resection during the same period. RESULTS: Ten out of 152 patients who had undergone a hepatic resection were diagnosed with cHCC-CC and thus included in this study (M : F=8 : 2, median age: 52+/-11.1 years). According to the parameters of the 7th American Joint Committee on Cancer T staging, there were 76 (50.0%), 44 (28.9%), 9 (5.9%), 18 (11.8%) and 5 (3.3%) patients with T stages 1, 2, 3a, 3b and 4, respectively. The overall survival period was longer in the HCC only group (68+/-40.4 months) than in the combined cHCC-CC group (23+/-40.1 months) (p<0.0001). The 5-year survival rate was 10% in the cHCC-CC group and 60% in the HCC group (p<0.0001). The disease free survival for patients with cHCC-HCC and HCC were 16+/-37.4 and 51+/-44.3 months, respectively (p<0.0001). Univariate analysis revealed that age, gender, transarterial chemoembolization (TACE), and T stage were statistically significant in terms of patient's overall survival. However, there were no significant clinicopathological factors identified by the multivariate analysis. CONCLUSIONS: Even after the hepatic resection in the HCC, the prognosis is poorer if the patient has cholangiocellular components compared to the usual HCC.
